HGH Fragment 176-191 Driada Medical 5mg

HGH Fragment 176-191 5mg

HGH fragment 176-191, also known as AOD9604, is a peptide derived from amino acids 176-191 of growth hormone. It specifically targets fat burning and has been extensively studied in both animal and human adipose tissue. Researchers have focused on exploring the potential of HGH fragment 176-191 for reducing fat mass in overweight individuals, as obesity is associated with various health problems such as heart disease, cancer, and diabetes.

Recombinant growth hormone was previously considered for the treatment of obesity; however, its long-term use was hampered by intolerance, insulin resistance, edema, and hypertension. To address these concerns, AOD9604, later known as HGH fragment 176-191, was developed.

Mechanism of action

The HGH fragment 176-191 increases fat oxidation and promotes lipolysis by reducing lipogenesis. This is achieved by acting directly on adipose tissue. The drug enhances the expression of the beta-3 adrenergic receptor gene, which plays a significant role in the destruction of fat cells by the sympathetic nervous system and in thermoregulation. However, this is not the only mechanism of the drug’s effect on lipolysis.

Ex vivo studies have shown that the HGH fragment significantly reduces lipogenic activity and increases lipolytic activity in adipose tissues. This increased catabolism is reflected in increased energy expenditure, glucose oxidation, and fat oxidation. The peptide also exhibited lipolytic and anti-lipogenic effects in isolated adipose tissues of rodents and humans. These results indicate that the HGH fragment alters lipid metabolism in adipose tissues, thereby reducing body weight gain in obese animals. Furthermore, its potent lipolytic and anti-lipogenic properties suggest its potential in the treatment of obesity in humans.

The HGH fragment offers the advantage of not having the side effects associated with growth hormone use. It does not bind to growth hormone receptors and acts exclusively on adipose and bone tissue. It is important to note that the peptide does not affect serum IGF-1 levels, further confirming that it does not act via IGF-1. Unlike growth hormone, the HGH fragment does not negatively impact carbohydrate metabolism or induce the formation of antibodies that could compromise its benefits.

Effects

• Main effect: Burning of subcutaneous fat
• A possible positive effect on cartilage with intra-articular administration is relevant for people with joint and ligament disorders, as well as for athletes. However, further research is needed to confirm this effect in humans.

Side effects

• Studies suggest that the use of HGH fragment is associated with minimal adverse effects. In rare cases, a temporary burning sensation and itching at the injection site may occur.

Use

Based on practical experience, the recommended dose of HGH fragment is usually a few micrograms per day, divided into 2-3 doses. Regarding the duration of treatment, there is currently no reliable data. Recommendations found online suggest a duration of several months based on the opinions and experiences of athletes. The duration of treatment should be in line with the desired results and influenced by other current medications, diet, and individual factors. Combining HGH fragment with other substances used in sports, such as growth hormone, growth hormone-releasing peptides, or IGF-1, may provide a synergistic effect for fat reduction. It is important to note that a low-fat diet can increase the effectiveness of this peptide.

Preparing a solution

To prepare a solution for injection, draw a diluent into a syringe and inject it into a vial containing the lyophilized powder. Tilt the vial so that the needle touches the wall of the vial, allowing the diluent to gradually flow downward. Gently mix the solution without shaking or shaking the vial until the lyophilized powder has completely dissolved, resulting in a clear liquid. Never mix different peptides in the same syringe to avoid degradation of the fragile peptide molecules.

Administration

• The injection can be administered subcutaneously or intramuscularly, depending on personal preference.

Conservation

• The liquid solution can be stored for approximately 21 days in the refrigerator at 2-8 degrees Celsius. The shelf life may be increased if bacteriostatic water is used during preparation.